Why the obesity drug market is about to get a lot more crowded

Not surprisingly, given the massive popularity of the obesity wunderkinds sold by Novo Nordisk and Eli Lilly, major competition is brewing. In fact, analysts say the obesity drug market is about to get a lot more crowded, with more than a dozen new therapies poised to launch by decade’s end.

Encouraged by the blockbuster debuts of Novo’s Wegovy in 2021 and Lilly’s Mounjaro in 2022 (the drug was subsequently approved for weight loss as Zepbound), pharma companies are vying to launch several alternative treatments, adding to a drug market which is expected to be the largest in pharma history.